Co-Diagnostics, Inc. CODX
Surgical & Medical Instruments & Apparatus · CIK 0001692415 · Fiscal year ends 1231
Revenue
$622.49K
Fiscal year ended 2025-12-31Operating income
-$50.17M
Fiscal year ended 2025-12-31Free cash flow
-$29.84M
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $10.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
| Float per share | $2.78 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
| Float / revenue | 16.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
| Float / equity | 0.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
Co-Diagnostics, Inc. (CODX) reported revenue of $622.49K and net income of -$46.90M for the fiscal year ended 2025-12-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from Co-Diagnostics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
Co-Diagnostics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|
| Revenue | $622.49K | $3.92M | $6.81M | $34.22M | $97.89M | $74.55M | $214.97K | $39.91K | $7.66K |
|---|
| Cost of revenue | $222.38K | $999.12K | $4.18M | $5.48M | $11.57M | $16.59M | $112.43K | $9.39K | $302 |
|---|
| Gross profit | $400.11K | $2.92M | $2.63M | $28.74M | $86.31M | $57.96M | $102.54K | $30.52K | $7.36K |
|---|
| Operating income | -$50.17M | -$40.08M | -$42.71M | -$26.98M | $46.06M | $41.69M | -$5.89M | -$6.12M | -$4.56M |
|---|
| Net income | -$46.90M | -$37.64M | -$35.33M | -$14.24M | $36.66M | $42.48M | -$6.20M | -$6.27M | -$6.96M |
|---|
| Research & development | $19.14M | $20.98M | $22.96M | $17.44M | $14.96M | $3.19M | $1.37M | $1.36M | $1.00M |
|---|
| Weighted-average diluted shares | shares 1.33M | shares 1.01M | shares 29.35M | shares 31.48M | shares 29.90M | shares 28.00M | shares 16.76M | —Unavailable | —Unavailable |
|---|
| Pretax income | -$48.51M | -$37.58M | -$38.11M | -$18.85M | $45.64M | $42.57M | -$6.20M | -$6.27M | -$6.96M |
|---|
| Income tax expense | -$1.62M | $57.37K | -$2.78M | -$4.61M | $8.98M | $90.54K | —Unavailable | —Unavailable | —Unavailable |
|---|
| Diluted EPS | $-35.25 | $-37.22 | $-1.20 | $-0.45 | $1.23 | $1.52 | $-0.37 | —Unavailable | —Unavailable |
|---|
| Selling, general & administrative | $11.44M | $20.64M | $21.14M | $21.61M | $24.95M | $12.94M | $4.56M | $4.74M | $3.52M |
|---|
| General & administrative | $9.06M | $16.16M | $14.28M | $14.26M | $11.55M | $8.28M | $3.50M | $3.57M | $3.10M |
|---|
| Selling & marketing | $2.38M | $4.48M | $6.86M | $7.34M | $13.40M | $4.67M | $1.06M | $1.17M | $426.71K |
|---|
Balance
Co-Diagnostics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|
| Cash & equivalents | $11.88M | $2.94M | $14.92M | $22.97M | $88.61M | $42.98M | $893.14K | $950.24K | $3.53M |
|---|
| Total assets | $24.74M | $63.56M | $95.32M | $123.09M | $160.03M | $71.24M | $2.22M | $1.55M | $4.66M |
|---|
| Current assets | $13.69M | $32.29M | $62.14M | $92.73M | $115.12M | $67.81M | $1.58M | $1.05M | $4.45M |
|---|
| Total liabilities | $4.11M | $9.69M | $9.31M | $8.57M | $25.56M | $4.54M | $478.07K | $2.61M | $811.80K |
|---|
| Current liabilities | $3.54M | $7.32M | $5.75M | $3.87M | $12.60M | $4.06M | $328.07K | $2.35M | $628.26K |
|---|
| Total equity incl. NCI | $20.63M | $53.88M | $85.58M | $114.52M | $134.48M | $66.70M | $1.74M | -$1.06M | $3.85M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | $992.40K | $1.07M | $1.66M | $5.31M | $2.00M | $8.00M | $197.17K | $18.15K | $9.07K |
|---|
| Accounts receivable | $190.38K | $132.57K | $303.93K | $3.45M | $20.84M | $12.14M | $131.38K | $13.42K | —Unavailable |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $14.71M | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $1.91M | $277.72K |
|---|
| Accounts payable | $1.88M | $3.29M | $1.48M | $952.30K | $607.51K | $598.32K | $5.96K | $148.97K | $40.82K |
|---|
Cash flow
Co-Diagnostics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|
| Operating cash flow | -$29.14M | -$29.16M | -$22.08M | $6.57M | $41.08M | $28.17M | -$5.53M | -$4.08M | -$3.21M |
|---|
| Capital expenditures | $700.05K | $748.35K | $1.37M | $1.43M | $669.46K | $774.40K | $113.25K | $41.34K | $129.31K |
|---|
| Investing cash flow | $26.27M | $17.07M | $15.39M | -$58.17M | $4.10M | -$5.82M | -$435.25K | -$380.34K | -$189.31K |
|---|
| Financing cash flow | $11.81M | $103.91K | -$1.36M | -$14.03M | $450.40K | $19.74M | $5.90M | $1.88M | $5.94M |
|---|
| Net change in cash | $8.95M | -$11.98M | -$8.06M | -$65.63M | $45.63M | $42.08M | -$57.10K | -$2.58M | $2.54M |
|---|
| Stock-based compensation | $2.25M | $5.43M | $8.34M | $7.54M | $5.51M | $2.74M | $1.09M | $1.33M | $2.03M |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | $1.36M | $14.21M | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | $1.11M | $1.38M | $1.23M | $1.28M | $335.36K | $138.64K | $65.90K | $50.76K | $45.76K |
|---|
Derived
Co-Diagnostics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|
| Free cash flow | -$29.84M | -$29.90M | -$23.45M | $5.14M | $40.41M | $27.39M | -$5.64M | -$4.12M | -$3.34M |
|---|
| Gross margin | 64.3% | 74.5% | 38.6% | 84.0% | 88.2% | 77.7% | 47.7% | 76.5% | 96.1% |
|---|
| Operating margin | -8058.8% | -1023.7% | -626.9% | -78.8% | 47.1% | 55.9% | -2741.6% | -15328.6% | -59567.6% |
|---|
| FCF margin | -4793.2% | -763.8% | -344.2% | 15.0% | 41.3% | 36.7% | -2622.8% | -10326.4% | -43601.0% |
|---|
| SBC / revenue | 361.1% | 138.8% | 122.4% | 22.0% | 5.6% | 3.7% | 506.3% | 3338.4% | 26546.0% |
|---|
| Current ratio | 3.87x | 4.41x | 10.81x | 23.94x | 9.14x | 16.69x | 4.83x | 0.45x | 7.09x |
|---|
| Revenue YoY growth | -84.1% | -42.5% | -80.1% | -65.0% | 31.3% | 34579.9% | 438.6% | 420.9% | —Unavailable |
|---|
| Net margin | -7533.6% | -961.4% | -518.7% | -41.6% | 37.5% | 57.0% | -2882.0% | -15714.3% | -90827.9% |
|---|
| R&D / revenue | 3074.3% | 535.9% | 337.1% | 51.0% | 15.3% | 4.3% | 638.0% | 3410.5% | 13092.8% |
|---|
| CapEx / revenue | 112.5% | 19.1% | 20.0% | 4.2% | 0.7% | 1.0% | 52.7% | 103.6% | 1687.6% |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | 19.7% | 0.2% | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CODX in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.